Literature DB >> 30418215

Morphine Exacerbates Postfracture Nociceptive Sensitization, Functional Impairment, and Microglial Activation in Mice.

Wen-Wu Li1, Karen-Amanda Irvine, Peyman Sahbaie, Tian-Zhi Guo, Xiao-You Shi, Vivianne L Tawfik, Wade S Kingery, J David Clark.   

Abstract

BACKGROUND: Emerging evidence suggests that opioid use immediately after surgery and trauma may worsen outcomes. In these studies, the authors aimed to determine whether morphine administered for a clinically relevant time period (7 days) in a tibia fracture orthopedic surgery model had adverse effects on postoperative recovery.
METHODS: Mice were given morphine twice daily for 7 days after unilateral tibial fracture and intramedullary pin fixation to model orthopedic surgery and limb trauma. Mechanical allodynia, limb-specific weight bearing, gait changes, memory, and anxiety were measured after injury. In addition, spinal cord gene expression changes as well as glial activation were measured. Finally, the authors assessed the effects of a selective Toll-like receptor 4 antagonist, TAK-242, on nociceptive and functional changes after injury.
RESULTS: Tibial fracture caused several weeks of mechanical nociceptive sensitization (F(1, 216) = 573.38, P < 0.001, fracture + vehicle vs. sham + vehicle, n = 10 per group), and this change was exacerbated by the perioperative administration of morphine (F(1, 216) = 71.61, P < 0.001, fracture + morphine vs. fracture + vehicle, n = 10 per group). In additional testing, injured limb weight bearing, gait, and object location memory were worse in morphine-treated fracture mice than in untreated fracture mice. Postfracture expression levels of several genes previously associated with opioid-induced hyperalgesia, including brain-derived neurotrophic factor and prodynorphin, were unchanged, but neuroinflammation involving Toll-like receptor 4 receptor-expressing microglia was observed (6.8 ± 1.5 [mean ± SD] cells per high-power field for fracture + vehicle vs. 12 ± 2.8 fracture + morphine, P < 0.001, n = 8 per /group). Treatment with a Toll-like receptor 4 antagonist TAK242 improved nociceptive sensitization for about 2 weeks in morphine-treated fracture mice (F(1, 198) = 73.36, P < 0.001, fracture + morphine + TAK242 vs. fracture + morphine, n = 10 per group).
CONCLUSIONS: Morphine treatment beginning at the time of injury impairs nociceptive recovery and other outcomes. Measures preventing glial activation through Toll-like receptor 4 signaling may reduce the adverse consequences of postoperative opioid administration.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30418215      PMCID: PMC6349476          DOI: 10.1097/ALN.0000000000002495

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  55 in total

1.  Morphine tolerance and transcription factor expression in mouse spinal cord tissue.

Authors:  X Li; J D Clark
Journal:  Neurosci Lett       Date:  1999-09-10       Impact factor: 3.046

2.  Time-to-Cessation of Postoperative Opioids: A Population-Level Analysis of the Veterans Affairs Health Care System.

Authors:  Seshadri C Mudumbai; Elizabeth M Oliva; Eleanor T Lewis; Jodie Trafton; Daniel Posner; Edward R Mariano; Randall S Stafford; Todd Wagner; J David Clark
Journal:  Pain Med       Date:  2016-04-15       Impact factor: 3.750

3.  5-hydroxytryptamine type 3 receptor modulates opioid-induced hyperalgesia and tolerance in mice.

Authors:  De-Yong Liang; XiangQi Li; J David Clark
Journal:  Anesthesiology       Date:  2011-05       Impact factor: 7.892

4.  Different immune cells mediate mechanical pain hypersensitivity in male and female mice.

Authors:  Robert E Sorge; Josiane C S Mapplebeck; Sarah Rosen; Simon Beggs; Sarah Taves; Jessica K Alexander; Loren J Martin; Jean-Sebastien Austin; Susana G Sotocinal; Di Chen; Mu Yang; Xiang Qun Shi; Hao Huang; Nicolas J Pillon; Philip J Bilan; YuShan Tu; Amira Klip; Ru-Rong Ji; Ji Zhang; Michael W Salter; Jeffrey S Mogil
Journal:  Nat Neurosci       Date:  2015-06-29       Impact factor: 24.884

5.  The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome.

Authors:  Wen-Wu Li; Tian-Zhi Guo; Deyong Liang; Xiaoyou Shi; Tzuping Wei; Wade S Kingery; J David Clark
Journal:  Pain       Date:  2009-10-22       Impact factor: 6.961

6.  The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors.

Authors:  L R Poree; T Z Guo; W S Kingery; M Maze
Journal:  Anesth Analg       Date:  1998-10       Impact factor: 5.108

7.  Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision.

Authors:  DeYong Liang; Xiaoyou Shi; Yanli Qiao; Martin S Angst; David C Yeomans; J David Clark
Journal:  Mol Pain       Date:  2008-02-22       Impact factor: 3.395

8.  Toll-like receptor 4 mutant and null mice retain morphine-induced tolerance, hyperalgesia, and physical dependence.

Authors:  Theresa Alexandra Mattioli; Heather Leduc-Pessah; Graham Skelhorne-Gross; Chris J B Nicol; Brian Milne; Tuan Trang; Catherine M Cahill
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

9.  Epigenetic regulation of spinal cord gene expression contributes to enhanced postoperative pain and analgesic tolerance subsequent to continuous opioid exposure.

Authors:  Peyman Sahbaie; De-Yong Liang; Xiao-You Shi; Yuan Sun; J David Clark
Journal:  Mol Pain       Date:  2016-04-18       Impact factor: 3.395

Review 10.  Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward.

Authors:  Mark R Hutchinson; Sondra T Bland; Kirk W Johnson; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  ScientificWorldJournal       Date:  2007-11-02
View more
  8 in total

Review 1.  Assessment, Quantification, and Management of Fracture Pain: from Animals to the Clinic.

Authors:  Luke G McVeigh; Anthony J Perugini; Jill C Fehrenbacher; Fletcher A White; Melissa A Kacena
Journal:  Curr Osteoporos Rep       Date:  2020-10       Impact factor: 5.096

2.  Fentanyl-induced hyperalgesia and analgesic tolerance in male rats: common underlying mechanisms and prevention by a polyamine deficient diet.

Authors:  Emilie Laboureyras; Meric Ben Boujema; Annie Mauborgne; John Simmers; Michel Pohl; Guy Simonnet
Journal:  Neuropsychopharmacology       Date:  2021-10-07       Impact factor: 7.853

3.  Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats.

Authors:  Suzanne M Green-Fulgham; Jayson B Ball; Andrew J Kwilasz; Timothy Fabisiak; Steven F Maier; Linda R Watkins; Peter M Grace
Journal:  Pain       Date:  2019-11       Impact factor: 7.926

4.  Sex differences in neuro(auto)immunity and chronic sciatic nerve pain.

Authors:  Katja Linher-Melville; Anita Shah; Gurmit Singh
Journal:  Biol Sex Differ       Date:  2020-11-12       Impact factor: 5.027

Review 5.  What Did We Learn About Fracture Pain from Animal Models?

Authors:  Andreea Radulescu; Fletcher A White; Chantal Chenu
Journal:  J Pain Res       Date:  2022-09-13       Impact factor: 2.832

Review 6.  Modulatory Potential of Cannabidiol on the Opioid-Induced Inflammatory Response.

Authors:  Clare T Johnson; Heather B Bradshaw
Journal:  Cannabis Cannabinoid Res       Date:  2021-06

7.  Distinct non-inflammatory signature of microglia in post-mortem brain tissue of patients with major depressive disorder.

Authors:  Gijsje J L J Snijders; Marjolein A M Sneeboer; Alba Fernández-Andreu; Evan Udine; Marco P Boks; Paul R Ormel; Amber Berdenis van Berlekom; Hans C van Mierlo; Chotima Bӧttcher; Josef Priller; Towfique Raj; Elly M Hol; René S Kahn; Lot D de Witte
Journal:  Mol Psychiatry       Date:  2020-10-07       Impact factor: 13.437

8.  Fracture-induced pain-like behaviours in a femoral fracture mouse model.

Authors:  R Magnusdottir; S Gohin; F Ter Heegde; M Hopkinson; I F McNally; A Fisher; N Upton; A Billinton; C Chenu
Journal:  Osteoporos Int       Date:  2021-06-02       Impact factor: 4.507

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.